• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

单细胞分析表明,IL4I1 促进了卵巢癌的进展。

Single-cell analysis revealed that IL4I1 promoted ovarian cancer progression.

机构信息

Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, 100026, China.

出版信息

J Transl Med. 2021 Oct 30;19(1):454. doi: 10.1186/s12967-021-03123-7.

DOI:10.1186/s12967-021-03123-7
PMID:34717685
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8557560/
Abstract

BACKGROUND

Ovarian cancer was one of the leading causes of female deaths. Patients with OC were essentially incurable and portends a poor prognosis, presumably because of profound genetic heterogeneity limiting reproducible prognostic classifications.

METHODS

We comprehensively analyzed an ovarian cancer single-cell RNA sequencing dataset, GSE118828, and identified nine major cell types. Relationship between the clusters was explored with CellPhoneDB. A malignant epithelial cluster was confirmed using pseudotime analysis, CNV and GSVA. Furthermore, we constructed the prediction model (i.e., RiskScore) consisted of 10 prognosis-specific genes from 2397 malignant epithelial genes using the LASSO Cox regression algorithm based on public datasets. Then, the prognostic value of Riskscore was assessed with Kaplan-Meier survival analysis and time-dependent ROC curves. At last, a series of in-vitro assays were conducted to explore the roles of IL4I1, an important gene in Riskscore, in OC progression.

RESULTS

We found that macrophages possessed the most interaction pairs with other clusters, and M2-like TAMs were the dominant type of macrophages. C0 was identified as the malignant epithelial cluster. Patients with a lower RiskScore had a greater OS (log-rank P < 0.01). In training set, the AUC of RiskScore was 0.666, 0.743 and 0.809 in 1-year, 3-year and 5-year survival, respectively. This was also validated in another two cohorts. Moreover, downregulation of IL4I1 inhibited OC cells proliferation, migration and invasion.

CONCLUSIONS

Our work provide novel insights into our understanding of the heterogeneity among OCs, and would help elucidate the biology of OC and provide clinical guidance in prognosis for OC patients.

摘要

背景

卵巢癌是女性死亡的主要原因之一。OC 患者基本上无法治愈,预后不良,这可能是由于深刻的遗传异质性限制了可重复的预后分类。

方法

我们全面分析了一个卵巢癌单细胞 RNA 测序数据集 GSE118828,并鉴定了九个主要细胞类型。使用 CellPhoneDB 探索了簇之间的关系。通过伪时间分析、CNV 和 GSVA 确认了恶性上皮簇。此外,我们使用基于公共数据集的 LASSO Cox 回归算法从 2397 个恶性上皮基因中构建了由 10 个预后特异性基因组成的预测模型(即 RiskScore)。然后,通过 Kaplan-Meier 生存分析和时间依赖的 ROC 曲线评估 RiskScore 的预后价值。最后,进行了一系列体外实验来探索 Riskscore 中的重要基因 IL4I1 在 OC 进展中的作用。

结果

我们发现巨噬细胞与其他簇具有最多的相互作用对,并且 M2 样 TAMs 是巨噬细胞的主要类型。C0 被鉴定为恶性上皮簇。RiskScore 较低的患者 OS 更高(对数秩 P<0.01)。在训练集中,RiskScore 的 AUC 在 1 年、3 年和 5 年生存率分别为 0.666、0.743 和 0.809。这在另外两个队列中也得到了验证。此外,下调 IL4I1 抑制了 OC 细胞的增殖、迁移和侵袭。

结论

我们的工作为我们理解 OC 之间的异质性提供了新的见解,并将有助于阐明 OC 的生物学,并为 OC 患者的预后提供临床指导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fc3/8557560/7a27ae49a515/12967_2021_3123_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fc3/8557560/ae3aa5505c9d/12967_2021_3123_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fc3/8557560/c53d6f3bf2b0/12967_2021_3123_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fc3/8557560/3e5a45cb9067/12967_2021_3123_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fc3/8557560/0d5d4d05468e/12967_2021_3123_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fc3/8557560/86d93cc974af/12967_2021_3123_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fc3/8557560/ce5f2d93b4e0/12967_2021_3123_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fc3/8557560/7a27ae49a515/12967_2021_3123_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fc3/8557560/ae3aa5505c9d/12967_2021_3123_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fc3/8557560/c53d6f3bf2b0/12967_2021_3123_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fc3/8557560/3e5a45cb9067/12967_2021_3123_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fc3/8557560/0d5d4d05468e/12967_2021_3123_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fc3/8557560/86d93cc974af/12967_2021_3123_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fc3/8557560/ce5f2d93b4e0/12967_2021_3123_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fc3/8557560/7a27ae49a515/12967_2021_3123_Fig7_HTML.jpg

相似文献

1
Single-cell analysis revealed that IL4I1 promoted ovarian cancer progression.单细胞分析表明,IL4I1 促进了卵巢癌的进展。
J Transl Med. 2021 Oct 30;19(1):454. doi: 10.1186/s12967-021-03123-7.
2
IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy.IL4I1 在 M2 样巨噬细胞中促进神经胶质瘤的进展,是免疫治疗的一个有前途的靶点。
Front Immunol. 2024 Jan 5;14:1338244. doi: 10.3389/fimmu.2023.1338244. eCollection 2023.
3
Integration of scRNA-Seq and Bulk RNA-Seq to Analyse the Heterogeneity of Ovarian Cancer Immune Cells and Establish a Molecular Risk Model.整合单细胞RNA测序和批量RNA测序以分析卵巢癌免疫细胞的异质性并建立分子风险模型。
Front Oncol. 2021 Sep 21;11:711020. doi: 10.3389/fonc.2021.711020. eCollection 2021.
4
Single-cell RNA sequencing reveals that MYBL2 in malignant epithelial cells is involved in the development and progression of ovarian cancer.单细胞 RNA 测序揭示恶性上皮细胞中的 MYBL2 参与卵巢癌的发生和发展。
Front Immunol. 2024 Jul 29;15:1438198. doi: 10.3389/fimmu.2024.1438198. eCollection 2024.
5
Identification and verification of a ten-gene signature predicting overall survival for ovarian cancer.鉴定和验证一个十基因标志物,用于预测卵巢癌的总生存期。
Exp Cell Res. 2020 Oct 15;395(2):112235. doi: 10.1016/j.yexcr.2020.112235. Epub 2020 Aug 14.
6
The enhancer RNA ADCY10P1 is associated with the progression of ovarian cancer.增强子 RNA ADCY10P1 与卵巢癌的进展相关。
J Ovarian Res. 2022 May 14;15(1):61. doi: 10.1186/s13048-022-00987-1.
7
A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.基于免疫相关长非编码 RNA 的上皮性卵巢癌预后模型。
J Ovarian Res. 2022 Jan 15;15(1):8. doi: 10.1186/s13048-021-00930-w.
8
A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.一种基于共表达网络分析和五种长链非编码RNA表达水平的新型卵巢癌风险评分系统。
BMC Med Genet. 2019 Jun 10;20(1):103. doi: 10.1186/s12881-019-0832-9.
9
Identification of a novel nine-SnoRNA signature with potential prognostic and therapeutic value in ovarian cancer.鉴定新型九核仁小 RNA 标志物,其在卵巢癌中具有潜在的预后和治疗价值。
Cancer Med. 2022 May;11(10):2159-2170. doi: 10.1002/cam4.4598. Epub 2022 Feb 21.
10
Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.ETV5 在高级别浆液性卵巢癌中的生物学和预后价值。
J Ovarian Res. 2021 Nov 4;14(1):149. doi: 10.1186/s13048-021-00899-6.

引用本文的文献

1
Development of a relapse-related RiskScore model to predict the drug sensitivity and prognosis for patients with ovarian cancer.开发一种与复发相关的风险评分模型,以预测卵巢癌患者的药物敏感性和预后。
PeerJ. 2025 Aug 11;13:e19764. doi: 10.7717/peerj.19764. eCollection 2025.
2
Metabolism-associated marker gene-based predictive model for prognosis, targeted therapy, and immune landscape in ovarian cancer: an integrative analysis of single-cell and bulk RNA sequencing with spatial transcriptomics.基于代谢相关标记基因的卵巢癌预后、靶向治疗和免疫格局预测模型:单细胞和批量RNA测序与空间转录组学的综合分析
BMC Womens Health. 2025 May 17;25(1):233. doi: 10.1186/s12905-025-03750-y.
3

本文引用的文献

1
Overexpression of PLXDC2 in Stromal Cell-Associated M2 Macrophages Is Related to EMT and the Progression of Gastric Cancer.基质细胞相关M2巨噬细胞中PLXDC2的过表达与上皮-间质转化及胃癌进展相关。
Front Cell Dev Biol. 2021 May 28;9:673295. doi: 10.3389/fcell.2021.673295. eCollection 2021.
2
IL4I1 Is Expressed by Head-Neck Cancer-Derived Mesenchymal Stromal Cells and Contributes to Suppress T Cell Proliferation.IL4I1由头颈癌来源的间充质基质细胞表达,并有助于抑制T细胞增殖。
J Clin Med. 2021 May 13;10(10):2111. doi: 10.3390/jcm10102111.
3
The mechanism of lncRNA-CRNDE in regulating tumour-associated macrophage M2 polarization and promoting tumour angiogenesis.
Knockout IL4I1 affects macrophages to improve poor efficacy of CD19 CAR-T combined with PD-1 inhibitor in relapsed/refractory diffuse large B-cell lymphoma.
敲除IL4I1会影响巨噬细胞,从而改善CD19嵌合抗原受体T细胞(CAR-T)联合程序性死亡蛋白1(PD-1)抑制剂治疗复发/难治性弥漫性大B细胞淋巴瘤的疗效不佳问题。
J Transl Med. 2025 Jan 22;23(1):105. doi: 10.1186/s12967-024-06028-3.
4
IL-4-Induced Gene 1: A Potential Player in Myocardial Infarction.白细胞介素-4诱导基因1:心肌梗死中的一个潜在作用因子。
Rev Cardiovasc Med. 2024 Sep 20;25(9):337. doi: 10.31083/j.rcm2509337. eCollection 2024 Sep.
5
A clinical prognostic model related to T cells based on machine learning for predicting the prognosis and immune response of ovarian cancer.一种基于机器学习的与T细胞相关的临床预后模型,用于预测卵巢癌的预后和免疫反应。
Heliyon. 2024 Aug 24;10(17):e36898. doi: 10.1016/j.heliyon.2024.e36898. eCollection 2024 Sep 15.
6
Targeting amino acid-metabolizing enzymes for cancer immunotherapy.针对氨基酸代谢酶的癌症免疫疗法。
Front Immunol. 2024 Aug 14;15:1440269. doi: 10.3389/fimmu.2024.1440269. eCollection 2024.
7
The emerging role of circular RNAs in cisplatin resistance in ovarian cancer: From molecular mechanism to future potential.环状RNA在卵巢癌顺铂耐药中的新作用:从分子机制到未来潜力
Noncoding RNA Res. 2024 May 20;9(4):1280-1291. doi: 10.1016/j.ncrna.2024.05.005. eCollection 2024 Dec.
8
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma.NeoPembrOv 试验的免疫组学纵向分析鉴定了高级卵巢癌免疫抵抗的驱动因素。
Nat Commun. 2024 Jul 16;15(1):5932. doi: 10.1038/s41467-024-47000-5.
9
IL4I1: a novel molecular biomarker represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.IL4I1:一种新型分子生物标志物,代表炎症性肿瘤微环境,可精确预测膀胱癌的分子亚型和免疫治疗反应。
Front Pharmacol. 2024 May 30;15:1365683. doi: 10.3389/fphar.2024.1365683. eCollection 2024.
10
IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy.IL4I1 在 M2 样巨噬细胞中促进神经胶质瘤的进展,是免疫治疗的一个有前途的靶点。
Front Immunol. 2024 Jan 5;14:1338244. doi: 10.3389/fimmu.2023.1338244. eCollection 2023.
长链非编码 RNA-CRNDE 在调节肿瘤相关巨噬细胞 M2 极化并促进肿瘤血管生成中的作用机制。
J Cell Mol Med. 2021 May;25(9):4235-4247. doi: 10.1111/jcmm.16477. Epub 2021 Mar 20.
4
IL4I1 Accelerates the Expansion of Effector CD8 T Cells at the Expense of Memory Precursors by Increasing the Threshold of T-Cell Activation.IL4I1 通过提高 T 细胞激活阈值促进效应性 CD8 T 细胞的扩增而牺牲记忆前体细胞。
Front Immunol. 2020 Dec 4;11:600012. doi: 10.3389/fimmu.2020.600012. eCollection 2020.
5
Triple knockdown of CDC37, HSP90-alpha and HSP90-beta diminishes extracellular vesicles-driven malignancy events and macrophage M2 polarization in oral cancer.对细胞周期蛋白依赖性激酶37(CDC37)、热休克蛋白90α(HSP90-α)和热休克蛋白90β(HSP90-β)进行三联敲低可减少细胞外囊泡驱动的口腔癌恶性事件及巨噬细胞M2极化。
J Extracell Vesicles. 2020 May 31;9(1):1769373. doi: 10.1080/20013078.2020.1769373.
6
Tumor-associated macrophages promote human hepatoma Huh-7 cell migration and invasion through the Gli2/IGF-II/ERK1/2 axis by secreting TGF-β1.肿瘤相关巨噬细胞通过分泌 TGF-β1 沿 Gli2/IGF-II/ERK1/2 轴促进人肝癌 Huh-7 细胞迁移和侵袭。
Cancer Biol Ther. 2020 Nov 1;21(11):1041-1050. doi: 10.1080/15384047.2020.1824478. Epub 2020 Oct 21.
7
Breast cancer-associated macrophages promote tumorigenesis by suppressing succinate dehydrogenase in tumor cells.乳腺癌相关巨噬细胞通过抑制肿瘤细胞中的琥珀酸脱氢酶促进肿瘤发生。
Sci Signal. 2020 Oct 6;13(652):eaax4585. doi: 10.1126/scisignal.aax4585.
8
A newly defined risk signature, consisting of three mA RNA methylation regulators, predicts the prognosis of ovarian cancer.一种由三种mRNA甲基化调节因子组成的新定义风险特征可预测卵巢癌的预后。
Aging (Albany NY). 2020 Sep 20;12(18):18453-18475. doi: 10.18632/aging.103811.
9
EB virus-induced ATR activation accelerates nasopharyngeal carcinoma growth via M2-type macrophages polarization.EB 病毒诱导的 ATR 激活通过 M2 型巨噬细胞极化加速鼻咽癌生长。
Cell Death Dis. 2020 Sep 11;11(9):742. doi: 10.1038/s41419-020-02925-9.
10
IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression.IL4I1 是一种代谢免疫检查点,可激活 AHR 并促进肿瘤进展。
Cell. 2020 Sep 3;182(5):1252-1270.e34. doi: 10.1016/j.cell.2020.07.038. Epub 2020 Aug 19.